UNSPSC 51171805: Trimethobenzamide

This classification denotes an antiemetic agent with the molecular formula C21H28N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W2X096QY97, chemically known as 4-(2-dimethylaminoethoxy)-n-(3,4,5-trimethoxybenzoyl)benzylamine but generally known as trimethobenzamide, which bears US NIH Compound Identifier 5577. European Medicines Agency schedules Trimethobenzamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11309MIG.

UNSPSC 51171805 Trimethobenzamide is a Commodity code representing a specific pharmaceutical active ingredient. State and local opportunities tagged under this code show minimal alignment with the nominal drug name itself; instead, the recent activity reflects broader pharmaceutical procurement spanning generic multi-source drugs, over-the-counter products, and drug-testing services where trimethobenzamide may appear as one line item among hundreds. State and local issuing bodies procuring under this code include county community supervision and corrections departments, state health and human services agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions. The actual work being solicited is the supply of FDA-compliant pharmaceutical products with specified National Drug Codes, maintenance of licensed wholesaler relationships, certification against cGMP and drug supply chain security standards, and in some cases the operational delivery of specimen collection and drug-testing services to support correctional and health benefit programs.

Recent activity appears concentrated in Texas and Minnesota. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with a response deadline of July 23, 2026, seeking an estimated $600,000 contract over two years with optional renewals; the scope includes immunoassay screening and confirmation testing at two sites in the Dallas-Fort Worth area. The Texas Health and Human Services Commission issued a Request for Information in early April 2026 to explore direct-to-manufacturer pharmacy prescription programs as a market-intelligence phase preceding formal procurement. The Minnesota Department of Administration's Office of State Procurement, on behalf of the Minnesota Multistate Cooperative Purchasing Alliance, posted RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness on July 1, 2026. The code shows limited recent solicitation volume and does not reflect the kind of sustained procurement velocity that would indicate strong market demand for this specific drug at the state and local level.